Microbiome Assisted Tumor Microenvironment: Emerging Target of Breast Cancer

Malla, Rama Rao; Marni, Rakshmitha; Kumari, Seema; Chakraborty, Aninditha; Pappu, Lalitha

doi:10.1016/j.clbc.2021.09.002

Cited by 16 publications

(11 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In breast cancer, many immune-related pathways are abnormally regulated, thereby influencing the microenvironment, such as through immune cell infiltration [ 50 ]. Based on current literature, some believe that the TME is a potential treatment target in breast cancer [ 51 , 52 ]. To further demonstrate this conclusion, a drug sensitivity analysis was performed through which we identified significantly higher responses to agents, with the exception of lapatinib, in high-risk breast cancer.…”

Section: Discussionmentioning

confidence: 99%

Tumor microenvironment-related multigene prognostic prediction model for breast cancer

Hong

Zhang

Yao

et al. 2022

Aging

View full text Add to dashboard Cite

Background: Breast cancer is an invasive disease with complex molecular mechanisms. Prognosis-related biomarkers are still urgently needed to predict outcomes of breast cancer patients. Methods: Original data were download from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO). The analyses were performed using perl-5.32 and R-x64-4.1.1. Results: In this study, 1086 differentially expressed genes (DEGs) were identified in the TCGA cohort; 523 shared DEGs were identified in the TCGA and GSE10886 cohorts. Eight subtypes were estimated using non-negative matrix factorization clustering with significant differences seen in overall survival (OS) and progression-free survival (PFS) (P < 0.01). Univariate Cox analysis and least absolute shrinkage and selection operator (LASSO) regression analysis were performed to develop a related risk score related to the 17 DEGs; this score separated breast cancer into low-and high-risk groups with significant differences in survival (P < 0.01) and showed powerful effectiveness (TCGA all group: 1-year area under the curve [AUC] = 0.729, 3-year AUC = 0.778, 5-year AUC = 0.781). A nomogram prediction model was constructed using non-negative matrix factorization clustering, the risk score, and clinical characteristics. Our model was confirmed to be related with tumor microenvironment. Furthermore, DEGs in high-risk breast cancer were enriched in histidine metabolism (normalized enrichment score [NES] = 1.49, P < 0.05), protein export (NES = 1.58, P < 0.05), and steroid hormone biosynthesis signaling pathways (NES = 1.56, P < 0.05). Conclusions: We established a comprehensive model that can predict prognosis and guide treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Tumor microenvironment-related multigene prognostic prediction model for breast cancer

Hong

Zhang

Yao

et al. 2022

Aging

View full text Add to dashboard Cite

show abstract

“…Microbiota-induced changes in metabolic pathways are associated with the heterogeneity of breast cancer. Modified composition of the gut and breast microbiome promotes the progression of breast cancer ( 81 , 82 ). In this context, different breast microbiome was observed in women with benign or malignant disease.…”

Section: The Study Of Tumor Microbiome In Various Solid Malignanciesmentioning

confidence: 99%

Tumor microbiome – an integral part of the tumor microenvironment

et al. 2022

View full text Add to dashboard Cite

The tumor microenvironment (TME) plays a significant role in tumor progression and cancer cell survival. Besides malignant cells and non-malignant components, including immune cells, elements of the extracellular matrix, stromal cells, and endothelial cells, the tumor microbiome is considered to be an integral part of the TME. Mounting evidence from preclinical and clinical studies evaluated the presence of tumor type-specific intratumoral bacteria. Differences in microbiome composition between cancerous tissues and benign controls suggest the importance of the microbiome-based approach. Complex host-microbiota crosstalk within the TME affects tumor cell biology via the regulation of oncogenic pathways, immune response modulation, and interaction with microbiota-derived metabolites. Significantly, the involvement of tumor-associated microbiota in cancer drug metabolism highlights the therapeutic implications. This review aims to summarize current knowledge about the emerging role of tumor microbiome in various types of solid malignancies. The clinical utility of tumor microbiome in cancer progression and treatment is also discussed. Moreover, we provide an overview of clinical trials evaluating the role of tumor microbiome in cancer patients. The research focusing on the communication between the gut and tumor microbiomes may bring new opportunities for targeting the microbiome to increase the efficacy of cancer treatment and improve patient outcomes.

show abstract

“…Of note, microbiome signatures in the oncobiome correlate with survival in breast cancer, which underlines the importance of oncobiotic transformation in regulating breast cancer behavior [ 70 ]. The microbiome is now considered a component of the tumor microenvironment [ 93 ].…”

Section: Oncobiosis In Breast Cancermentioning

confidence: 99%

The involvement of oncobiosis and bacterial metabolite signaling in metastasis formation in breast cancer

Kovàcs

Mikó

Ujlaki

et al. 2021

Cancer Metastasis Rev

View full text Add to dashboard Cite

Breast cancer, the most frequent cancer in women, is characterized by pathological changes to the microbiome of breast tissue, the tumor, the gut, and the urinary tract. Changes to the microbiome are determined by the stage, grade, origin (NST/lobular), and receptor status of the tumor. This year is the 50th anniversary of when Hill and colleagues first showed that changes to the gut microbiome can support breast cancer growth, namely that the oncobiome can reactivate excreted estrogens. The currently available human and murine data suggest that oncobiosis is not a cause of breast cancer, but can support its growth. Furthermore, preexisting dysbiosis and the predisposition to cancer are transplantable. The breast’s and breast cancer’s inherent microbiome and the gut microbiome promote breast cancer growth by reactivating estrogens, rearranging cancer cell metabolism, bringing about a more inflammatory microenvironment, and reducing the number of tumor-infiltrating lymphocytes. Furthermore, the gut microbiome can produce cytostatic metabolites, the production of which decreases or blunts breast cancer. The role of oncobiosis in the urinary tract is largely uncharted. Oncobiosis in breast cancer supports invasion, metastasis, and recurrence by supporting cellular movement, epithelial-to-mesenchymal transition, cancer stem cell function, and diapedesis. Finally, the oncobiome can modify the pharmacokinetics of chemotherapeutic drugs. The microbiome provides novel leverage on breast cancer that should be exploited for better management of the disease.

show abstract

Microbiome Assisted Tumor Microenvironment: Emerging Target of Breast Cancer

Cited by 16 publications

References 119 publications

Tumor microenvironment-related multigene prognostic prediction model for breast cancer

Tumor microenvironment-related multigene prognostic prediction model for breast cancer

Tumor microbiome – an integral part of the tumor microenvironment

The involvement of oncobiosis and bacterial metabolite signaling in metastasis formation in breast cancer

Contact Info

Product

Resources

About